Advertisement covers EACS 2013

Building a Better HIV Drug: Nano-Formulated Medicines

December 18, 2013


Drivers for Developing Nanomedicine

Drivers for Developing Nanomedicine

There are different drivers for and against researching and developing nanomedicines, but the pros outweigh the cons, Owen asserted. On the downside, there can be issues with insolubility of active pharmaceutical ingredients, and the difficulty and cost of formulation during development can be high. However, the pros that nanomedicines could offer include a modified delivery profile, a solution to fed/fasted variability, an improvement in patient adherence, a reduction in pill burden and decreased adverse drug reactions.

Pre-clinical research has shown that nano-formulations have greater potency at lower dosage levels than conventional formulations. Furthermore, with intramuscular or intravenous delivery, there could be a sustained release of the drug and better targeting of the virus.

This article was provided by It is a part of the publication The 14th European AIDS Conference (EACS 2013).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.